Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05126147
Other study ID # 202101055MINB
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date March 21, 2022
Est. completion date December 31, 2024

Study information

Verified date January 2024
Source National Taiwan University Hospital
Contact Shyang-Rong Shih
Phone +886-2-23123456
Email srshih@ntu.edu.tw
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is aimed to investigate the effect of hydroxychloroquine in patients with mild Graves' orbitopathy (GO).


Description:

Graves' orbitopathy (GO) is one of the common manifestations of Graves' disease (GD), which results in proptosis, eyelid retraction, soft tissue swelling, diplopia or even visual acuity impairment. In addition, mental health and quality of life are often affected. In current guidelines, limited treatment options are suggested for patients with mild GO. Recently, cell study revealed that there are multiple effects of hydroxychloroquine (HCQ) on orbital fibroblasts in patients with mild GO, including suppression of cell proliferation, adipogenesis and production of hyaluronic acid, which poses a great potential in the treatment of mild GO clinically. This randomized controlled trial is aimed to investigate the effects of HCQ in patients with mild GO on the effects of ophthalmic outcomes, quality of life, orbital volumetry on orbital computed tomography, serum inflammatory and fibrosis markers.


Recruitment information / eligibility

Status Recruiting
Enrollment 108
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Mild GO according European Group on Graves' orbitopathy (EUGOGO) guidelines diagnosed by endocrinologist and ophthalmologist. - No previous treatment of GO except for eyedrops - Euthyroidism (normalized free T4 and TSH) for at least 2 months. If radioactive iodine is used for hyperthyroidism, euthyroidism needs to be achieved for at least 6 months. Exclusion Criteria: - Moderate-to-sever or sight-threatening GO according to EUGOGO guidelines diagnosed by endocrinologist and ophthalmologist. - Pregnancy - Drug or alcohol abuse - Unable to comply with the study protocol - Unable to obtain informed consent - Use of hydroxychloroquine or systemic steroid within 3 months prior to enrollment - History of side effects of hydroxychloroquine - History of retinopathy - Renal dysfunction (estimated glomerular filtration rate (eGFR) < 60ml/min) - Hepatic dysfunction (aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2 x upper limit) - Anemia (hemoglobin (Hb) < 10g/dl) - Neutropenia (absolute neutrophil count < 100/uL) - Thrombocytopenia (platelet (PLT) < 150000/uL) - Glucose-6-phosphate dehydrogenase (G6PD) deficiency - Porphyria cutaneous tarda - Allergy to 4-aminoquinoline

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Hydroxychloroquine
Compare the effects of hydroxychloroquine 200mg twice daily for 6 months with those without treatment.

Locations

Country Name City State
Taiwan National Taiwan University Hospital, Hsin-Chu branch Hsinchu
Taiwan National Taiwan University Hospital Taipei

Sponsors (1)

Lead Sponsor Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary The change of ophthalmic outcome The ophthalmic outcome is a composite outcome which includes three components: eyelid aperture, soft tissue involvement and exophthalmos.
The outcome is defined as "improvement" if any of the three components improves without deterioration of any other components. The outcome of "deterioration" is defined if upgrading of soft tissue involvement or evidence of worsening sight or optic nerve compression. The outcome of "stable" is defined if the ophthalmic outcome does not fit the definition of "improvement" or "deterioration".
at 24 weeks and 48 weeks
Secondary The change of quality of life (GO-QoL) The outcome is grading as improvement, stable and deterioration. Improvement is defined if there are more than 6 points increase in any of the category in GO-QoL. Deterioration is defined if there are more than 6 points decrease in any of the category in GO-QoL. Stable is defined if none of above criteria is achieved. at 24 weeks and 48 weeks
Secondary The change of muscle volume (cm^3) on computed tomography Change of muscle volume on noncontrast orbital CT at 24 weeks and 48 weeks
Secondary The change of fat volume (cm^3) on computed tomography Change of fat volume on noncontrast orbital CT at 24 weeks and 48 weeks
Secondary The change of orbital volume (cm^3) on computed tomography Change of orbital volume on noncontrast orbital CT at 24 weeks and 48 weeks
Secondary The change of muscle density on computed tomography The density of muscle is measured and recorded in Hounsfield units. at 24 weeks and 48 weeks
Secondary The change of fat density on computed tomography The density of fat is measured and recorded in Hounsfield units. at 24 weeks and 48 weeks
Secondary The change of diplopia score The Gorman diplopia score includes four categories: no diplopia(absent), diplopia when the patient is tired or awakening (intermittent), diplopia at extremes of gaze (inconstant), and continuous diplopia in the primary or reading position (constant). at 24 weeks and 48 weeks
Secondary The change of clinical activity score (CAS) Clinical activity score (CAS) is a 7-point scale using to evaluate the activity of GO in each eye. It includes 7 items to be scored respectively in each eye with minimum 0 point and maximum 7 points. More points indicate that GO in the eye is more active. The 7 items are listed as below:
Spontaneous orbital pain
Gaze evoked orbital pain
Eyelid swelling that is considered to be due to active GO
Eyelid erythema
Conjunctival redness that is considered to be due to active GO
Chemosis
Inflammation of caruncle OR plica
at 24 weeks and 48 weeks
Secondary The change of visual acuity Evaluation of visual acuity will be done by the same ophthalmologist at 24 weeks and 48 weeks
Secondary The change of antithyroid peroxidase antibody (anti-TPO) (IU/mL) Change of thyroid autoantibodies at 24 weeks and 48 weeks
Secondary The change of thyroglobulin antibody (TA) (IU/mL) Change of thyroid autoantibodies at 24 weeks and 48 weeks
Secondary The change of thyrotropin-binding inhibiting immunoglobulin (TBII) (%). Change of thyroid autoantibodies at 24 weeks and 48 weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05532072 - Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy. Early Phase 1
Completed NCT01727973 - Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy Phase 1/Phase 2
Recruiting NCT06112340 - A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Phase 2/Phase 3
Recruiting NCT05678374 - Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease
Recruiting NCT03708627 - Bimatoprost as a Treatment for Graves' Orbitopathy Early Phase 1
Not yet recruiting NCT06413043 - Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy N/A
Withdrawn NCT01379196 - Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy Phase 1/Phase 2
Recruiting NCT06275373 - The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Recruiting NCT06226545 - A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease Phase 2
Recruiting NCT01999790 - Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy N/A
Recruiting NCT03066076 - Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy Phase 3
Active, not recruiting NCT03122847 - Glucocorticoids and Bone in Graves' Ophthalmopathy
Terminated NCT01893450 - Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment N/A
Completed NCT00348413 - Thyroid Treatment Trial N/A
Completed NCT03498417 - Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy
Not yet recruiting NCT04598815 - Sirolimus for Graves' Orbitopathy (GO) Phase 2
Terminated NCT01114503 - A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease Phase 2
Completed NCT05793359 - Comparison of the Effectiveness of Two Glucocorticoid Regimens for Treatment of Graves' Orbitopathy
Completed NCT05775185 - Therapeutic Efficacy of Orbital Radiotherapy in Patients With Graves' Orbitopathy
Recruiting NCT02203682 - Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy Phase 2